Any current/future new fundraising through debt or equity?

No explicit mention of new major fundraising through debt or equity in the near term. Current net debt stands at approximately Rs.4,750 Crores. Expected amortization payments around Rs.550 Crores annually will gradually reduce debt. Some additional debt may be raised for new plants, such as the PET chips plant under construction. Overall net debt expected to remain around Rs.5,000 Crores in the near future. No new major capacity expansions announced beyond the currently ongoing projects. From FY2026 onwards, debt is expected to reduce as there are no significant new expansions planned.

Any current/future capex/capital investment/strategic investment?

Rs. 587 Crores capex for backward integration into pet chips plant at Panipat, India; commercial production expected by end of FY2024 or early FY2025. Pet chips plant commissioning planned in Egypt by end of FY2024 or slightly earlier. Aseptic packaging debottlenecking expected by September 2024, increasing capacity from 7 billion to 12 billion packs. No new major capacity expansion currently planned; focus on optimizing existing plants due to market uncertainties in Europe, America, and India. Some small capex possible for adding machines in value-added product lines but no new dedicated line

Future growth expectations in sales/revenue/volumes?

UFlex aims to bridge the revenue gap, targeting to reduce the 15.5% H1 FY2024 revenue decline to a 10% decline for the full year. EBITDA margins are expected to improve to around 11.5% annually. Packaging films volumes rose 6.6% Q-o-Q, indicating growth momentum. Flexible packaging volumes increased 21% sequentially and 7% Y-o-Y, reflecting strong demand. Liquid packaging volumes are slightly up Y-o-Y by 0.2%. Q4 FY2024 is expected to see better volumes and margins, especially from aseptic packaging due to seasonality. Overseas markets like America are expected to improve further i

Future growth expectations in earnings/operating earnings/profits/EPS?

H1 FY2024 revenue down 15.5% YoY; targeting to reduce annual revenue decline to 10% for full year. Aiming for an EBITDA margin of about 11.5% on an annualized basis FY2024. Q2 FY2024 EBITDA improved sequentially by 33.6% to Rs.406 Cr; quarterly margin at 12%, up from 9.3% in Q1. Expect further margin improvement in Q3 and Q4 driven by increased volumes, especially in liquid packaging business during Q4 seasonality. Overseas EBITDA expected to stabilize with positive trends in Americas; Europe remains uncertain. No specific EPS guidance given, but PAT improved to Rs.63 Cr in Q2 from loss in Q1;

IN US

Sale is live|00:00:00left today

Uflex LtdQ3 FY23Industrial Products

Uflex Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹417P/E: 12.1Market Cap: ₹2.9K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→UFlex aims to bridge the revenue gap, targeting to reduce the 15.5% H1 FY2024 revenue decline to a 10% decline for the full year.
→EBITDA margins are expected to improve to around 11.5% annually.
→Packaging films volumes rose 6.6% Q-o-Q, indicating growth momentum.
→Flexible packaging volumes increased 21% sequentially and 7% Y-o-Y, reflecting strong demand.
→Liquid packaging volumes are slightly up Y-o-Y by 0.2%.
→Q4 FY2024 is expected to see better volumes and margins, especially from aseptic packaging due to seasonality.
→Overseas markets like America are expected to improve further in Q3 and Q4, while Europe remains uncertain.
→India is showing robust volumes but margin pressure due to overcapacity.
→Capacity expansion projects (PET chips plant in India and Egypt, aseptic packaging debottlenecking) will enhance production by FY2024-end or early FY2025.

Margin guidance

Category 3

→H1 FY2024 revenue down 15.5% YoY; targeting to reduce annual revenue decline to 10% for full year.
→Aiming for an EBITDA margin of about 11.5% on an annualized basis FY2024.
→Q2 FY2024 EBITDA improved sequentially by 33.6% to Rs.406 Cr; quarterly margin at 12%, up from 9.3% in Q1.
→Expect further margin improvement in Q3 and Q4 driven by increased volumes, especially in liquid packaging business during Q4 seasonality.
→Overseas EBITDA expected to stabilize with positive trends in Americas; Europe remains uncertain.
→No specific EPS guidance given, but PAT improved to Rs.63 Cr in Q2 from loss in Q1; full-year still expects loss reduction.
→Overseas business EBITDA normalization anticipated by FY2025, with potential for better earnings post that.
→Growth initiatives include expansion in sustainable packaging, PET chips plants, and aseptic packaging capacity expansion by Sept 2024.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of new major fundraising through debt or equity in the near term.
→Current net debt stands at approximately Rs.4,750 Crores.
→Expected amortization payments around Rs.550 Crores annually will gradually reduce debt.
→Some additional debt may be raised for new plants, such as the PET chips plant under construction.
→Overall net debt expected to remain around Rs.5,000 Crores in the near future.
→No new major capacity expansions announced beyond the currently ongoing projects.
→From FY2026 onwards, debt is expected to reduce as there are no significant new expansions planned.

Order book

The transcript does not explicitly mention specific details about UFlex Limited's current or expected order book or pending orders. However, some related insights include: - Volume growth noted in flexible packaging (21% Q-o-Q) and packaging films (6.6% Q-o-Q) indicates healthy demand. - The overseas business, especially in America, is showing improvement, with volumes expected to pick up by Q4. - Certain capacity expansions and projects (e.g., pet chips plant, aseptic packaging capacity increase from 7 bn to 12 bn packs) are underway, signaling preparation for higher order fulfillment. - The company is monitoring market softness overseas and expects normalization possibly by FY2025 for certain businesses. - No direct quantitative data on order book size or pending orders is provided in the transcript.

Capex plans

Yes

→Rs. 587 Crores capex for backward integration into pet chips plant at Panipat, India; commercial production expected by end of FY2024 or early FY2025.
→Pet chips plant commissioning planned in Egypt by end of FY2024 or slightly earlier.
→Aseptic packaging debottlenecking expected by September 2024, increasing capacity from 7 billion to 12 billion packs.
→No new major capacity expansion currently planned; focus on optimizing existing plants due to market uncertainties in Europe, America, and India.
→Some small capex possible for adding machines in value-added product lines but no new dedicated lines envisioned.
→PET expansion plants in India and Egypt are considered final expansion with no further expansion planned currently.

How does Uflex Ltd rank vs peers in Industrial Products?

Pro feature

1Uflex Ltd

Rev 4Mar 3

See full Industrial Products sector rankings

Want more stocks like Uflex Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio